ClinicalTrials.gg
RecruitingNCT06894303Updated May 20, 2026

Evaluation of Remote Programming of Cochlear Implants in Routine Cochlear Implant Follow-up

An observational study in Cochlear Hearing Loss, sponsored by Advanced Bionics AG. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by Advanced Bionics AG (part of Sonova AG) · Observational

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
51
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Hearing Loss, Sensorineural by Sonova AG — 4 open to participants now, 4 under way, none of them phase 3. Hearing Loss, Sensorineural · Sonova AG.

Started
2025
with 1 other
Observational
7 of 28
2 open now
Registered
28th of 28
by date

Among the 28 studies in Hearing Loss, Sensorineural by Sonova AG, this one is one of 2 that started in 2025, is one of 7 observational ones, and was the 28th registered.

Hearing Loss, Sensorineural

348 studies on the registry are indexed under Hearing Loss, Sensorineural; 103 are open to participants now.

Browse Hearing Loss, Sensorineural studies →

Open to participants now

4 of the 28 studies in Hearing Loss, Sensorineural by Sonova AG are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 70 Hearing Loss, Sensorineural studies recruiting now, 39 (56%) set no upper age limit and 19 (27%) stop at 75 or younger; 26 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Hearing Loss, Sensorineural by Sonova AG, or all of them as a file.
02

Study summary

This is a prospective and monocentric clinical investigation, non-interventional and non-randomized. The overall goal of this clinical study is to generate additional clinical data confirming the safety and efficacy of the remote programming functionality of Target CI version 1.5 and the AB Remote Support app. Hearing outcomes are expected to be similar whether a study subject's sound processor is programmed in the traditional method in the audiologist's office or whether programming is performed via remote fitting. Therefore, the study uses a non-inferiority design to determine whether sentence recognition in noise is no worse with remote fitting than in an in-office setting.

03

Conditions studied

  • Cochlear Hearing Loss
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Advanced Bionics adults CI users

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to provide
  • Ability to give feedback on hearing impressions
  • Aged 18 years of age or older
  • Implanted with a HiResolution Bionic Ear System (HiRes 90K or HiRes 90K Advantage or HiRes Ultra or HiRes Ultra 3D) on at least one side

    • Group 1 - Unilateral: no hearing device except contralateral routing of signals (CROS) device on the contralateral side
    • Group 2 - Bilateral: implanted on both sides
    • Group 3 - Bimodal: hearing aid on the contralateral side
  • Minimum of six months of cochlear implant experience
  • Minimum of one month experience with a Naída CI M or Sky CI M sound processor
  • Fluent in French language
  • Ability to be tested via speech perception test in noise
  • Smartphone user

Exclusion criteria

Exclusion Criteria:

  • Clinical presentation indicative of potential implanted device malfunction
  • Unrealistic expectations regarding potential benefits, risks and limitations of the device as determined by the Investigator
  • Unwillingness or inability of subject to comply with all investigational requirements as determined by the Investigator

Pregnancy and breast-feeding are not exclusion criteria.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
51 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group 1

    Unilateral users

    Device: Target CI v1.5 remote programming

  • Group 2

    Bilateral users

    Device: Target CI v1.5 remote programming

  • Group 3

    Bimodal users

    Device: Target CI v1.5 remote programming

Interventions

  • DeviceTarget CI v1.5 remote programming

    Use of the remote programming function of Target CI v1.5 and the AB remote support application

06

What researchers measure

Primary outcomes

  1. 50% SRT measured as signal to noise ratio in DB (French Matrix test in noise)

    The primary efficacy objective is to demonstrate that speech recognition in noise after remote fitting is no worse than speech recognition in noise after in-office fitting.

    Time frame: one-month chronic use of remotely fitted sound processor

Secondary outcomes

  1. Score in the Lafon phoneme test in quiet

    The secondary efficacy objective is to demonstrate that speech recognition in quiet after remote fitting is no worse than speech recognition in quiet after in-office fitting.

    Time frame: one-month chronic use of remotely fitted sound processor

07

Study locations

1 of 1 sites recruiting
  • Groupement Hospitalier Pitié Salpêtrière
    Paris, 75013, France
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.

Of 42 observational studies under Hearing Loss, Sensorineural, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 13. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2025
First posted
Mar 25, 2025
StartActual
Feb 3, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06894303
Responsible party
Sponsor
First posted
Mar 25, 2025
Start date
Feb 3, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 20, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion